Array BioPharma Rallies on Late-Stage Win
Array BioPharma reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial.
All Work
Chris Lange
Lakeland Stumbles on Mixed Earnings
Lakeland Industries reported mixed fiscal 2016 third-quarter financial results after the markets closed on Tuesday.
Are Inland Real Estate Shareholders Getting Enough in the Merger?
Inland Real Estate has announced that it entered into a definitive agreement to be acquired by real estate funds managed by DRA Advisors.
Pacira Pharma Soars on Settled FDA Case
Pacira Pharmaceuticals announced that it achieved an amicable resolution with the FDA for a lawsuit filed earlier this year that effectively lifts the restriction on its Exparel.
Why Neothetics Is Getting Destroyed
Neothetics Inc. (NASDAQ: NEOT) was absolutely crashed in Tuesday’s session after announcing top-line results from a late stage trial that fell short.
What to Expect From Oracle Earnings
Oracle is scheduled to report its fiscal second-quarter financial results after the markets close on Wednesday.
Spark Therapeutics Files for Secondary Offering
Spark Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering.
Should Anyone Be Surprised by 3M’s Lower Guidance?
Reflecting the realities of a continued slow-growth global economy, 3M expects 2015 full-year organic growth to be lower than previous guidance.
Short Sellers Back Off Lumber Liquidators
This year has not a good one for Lumber Liquidators, but its shares traded up sharply Tuesday morning.
FuelCell Falls Short on the Bottom Line
FuelCell Energy reported its fiscal fourth-quarter financial results after the markets closed on Monday.
What to Expect From FedEx Earnings
FedEx is scheduled to report its fiscal second-quarter financial results after the markets close on Wednesday.
AcelRx Tanks on Pre-NDA Results
AcelRx intends to pursue an ARX-04 indication for moderate-to-severe pain in a medically supervised setting. However, this might be farther out than investors anticipated.
SEC Freezes Assets in Penny Stock Sports Scam
The SEC has announced fraud charges and a court-ordered asset freeze obtained against a Florida-based penny stock company.
Newell Rubbermaid Moves to Acquire Jarden
Newell Rubbermaid and Jarden announced that they have entered into a definitive agreement to combine, but investors don’t seem overly thrilled.
Underwriters Make Up Their Minds on Match Following Quiet Period
Match Group Inc. (NASDAQ: MTCH) is all about bringing people together, as perhaps the largest conglomerate of dating sites and services in the world. This company only recently became public and people are still…
How Analysts View Mimecast Post-IPO
Analysts are now just able to weigh in on Mimecast and where it stands relative to other firms in the cybersecurity field.
How Analysts View Square After the Quiet Period
Many investors did not know what to expect from the Square IPO, much less the stock, but now that we are exiting the quiet period the underwriters will be able to have their say.
What Atara Bio Has Under the Hood After Kidney Drug Failure
Atara Biotherapeutics announced results from its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting in patients with end stage renal disease.
Could This New Deal Double Akebia Therapeutics?
Akebia Therapeutics led the bulls early on Monday following news of what looks like a big commercialization partnership in Asia.
Top 6 Earnings for the Week Ahead
24/7 Wall St. has put together a preview of Oracle, Rite Aid and some other major companies reporting their quarterly results this week.